fig3

Figure 3. LINC01133 regulates cisplatin resistance and malignant behavior in LUAD. (A) Verification of the relative LINC01133 expression levels in each transfected cell group by qRT-PCR; (B) Effect of LINC01133 expression on cisplatin sensitivity in each cell group, as detected by a CCK-8 assay, with IC₅₀ values calculated from dose-response curves; (C) Role of LINC01133 expression in the proliferative capacity of each cell group, as measured through a CCK-8 assay; (D) Role of LINC01133 expression in the migratory and invasive capabilities of every cell group, as measured through a Transwell assay. Scale bar: 50 μm. Nonlinear regression analysis was conducted to fit the dose-response curves. Comparisons among multiple group means were completed with one-way ANOVA. ^*P < 0.05; ^***P < 0.001; ns: not significant. LUAD: Lung adenocarcinoma; qRT-PCR: quantitative reverse transcription-polymerase chain reaction; CCK-8: Cell Counting Kit-8; IC₅₀: half-maximal inhibitory concentration; ANOVA: analysis of variance; DDP: cisplatin.